Corient Private Wealth
PTCT icon

Corient Private Wealth’s PTC Therapeutics PTCT Stock Holding History

Corient Private Wealth’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.23M Buy
+15,115
New +$1.09M ﹤0.01% 1684

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Corient Private Wealth's PTCT Position: Q2 2026 in Review

Corient Private Wealth opened a new position in PTC Therapeutics (PTCT) in Q2 2026: 15,115 shares worth $1.23M. The stake represents ﹤0.01% of the portfolio and ranks #1684 among its holdings.

382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Corient Private Wealth held 15,115 shares of PTC Therapeutics worth $1.23M as of Q2 2026.
  • PTC Therapeutics was a new Corient Private Wealth position in Q2 2026.
  • PTC Therapeutics made up ﹤0.01% of Corient Private Wealth's portfolio in Q2 2026, its #1684 holding.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Corient Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.